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Abstract
Neonatal seizures are common in the neonatal intensive care unit. Clinicians treat these
seizures with several anti-epileptic drugs (AEDs) to reduce seizures in a neonate. Current
AEDs exhibit sub-optimal efficacy and several randomized control trials (RCT) of novel
AEDs are planned. The aim of this study was to measure the influence of trial design on the
required sample size of a RCT. We used seizure time courses from 41 term neonates with
hypoxic ischaemic encephalopathy to build seizure treatment trial simulations. We used
five outcome measures, three AED protocols, eight treatment delays from seizure onset
(Td) and four levels of trial AED efficacy to simulate different RCTs. We performed power
calculations for each RCT design and analysed the resultant sample size. We also
assessed the rate of false positives, or placebo effect, in typical uncontrolled studies. We
found that the false positive rate ranged from 5 to 85% of patients depending on RCT
design. For controlled trials, the choice of outcome measure had the largest effect on sam-
ple size with median differences of 30.7 fold (IQR: 13.7–40.0) across a range of AED proto-
cols, Td and trial AED efficacy (p<0.001). RCTs that compared the trial AED with positive
controls required sample sizes with a median fold increase of 3.2 (IQR: 1.9–11.9; p<0.001).
Delays in AED administration from seizure onset also increased the required sample size
2.1 fold (IQR: 1.7–2.9; p<0.001). Subgroup analysis showed that RCTs in neonates treated
with hypothermia required a median fold increase in sample size of 2.6 (IQR: 2.4–3.0) com-
pared to trials in normothermic neonates (p<0.001). These results show that RCT design
has a profound influence on the required sample size. Trials that use a control group,
appropriate outcome measure, and control for differences in Td between groups in analysis
will be valid and minimise sample size.
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Introduction
Evidence-based guidelines of drug treatments require studies where the drug effect is quantita-
tively measured and statistically compared to an alternative treatment or placebo. Key elements
of successful trial designs include the choice of relevant outcome measure(s) and sample size.
Selection of the outcome measure is typically a compromise betweenwhat is known to be
important in pathophysiology and what is practically possible.While the sample size must be
selected so that it is large enough to demonstrate statistical significance of a clinically relevant
effect, there is a practical need to minimize the sample size via trial design in order to reduce
the cost and duration of trials in vulnerable patient groups with rare conditions. The details of
RCT design are, therefore, critical when interpreting study findings; particularly when study
findings lead to a change in clinical practice.
Measuring treatment outcome is challenging when the natural course of the illness is vari-
able and has a tendency to improve [1, 2]. It becomes evenmore difficultwhen the natural
duration of the illness is short relative to the timing of treatment protocols [3]. Many neurolog-
ical illnesses, such as status epilepticus, and migraine, are well known to have highly variable
and self-limiting time courses. This is further complicated by the fact that the partial effective-
ness of existingmedications (such as phenobarbitone) may preclude the use of a placebo result-
ing instead in the use of a positive control group [4, 5].
Seizures in neonates present a particular challenge in this context because seizures tend to
resolve within tens of hours, leaving little time to observe treatment effects [6, 7]. In addition,
seizure occurrence is highly variable across neonates and varies with aetiology [7–10]. It is gen-
erally accepted that the accumulated duration of seizures, or seizure burden, as measured by
multi-channel EEG, should be the quantitative measure of choice when assessing anti-epileptic
drug (AED) efficacy [4, 5, 11–13]. This is based on the assumption that a high seizure burden
causes further damage to the already compromised neonatal brain [14–16]. An evidence based
AED trial should, therefore, be powered so that it takes into account the natural time course of
neonatal seizures. Otherwise, a bias in outcome towards a positive treatment effect could be
introduced. It has been difficult to accurately power a neonatal AED trial a priori, due to lim-
ited data on the temporal behaviour of seizures over a period of days. Recent advances in long
term EEGmonitoring have shed light onto the temporal evolution of neonatal seizures which
will improve power calculations [7, 10].
In the present work, we aimed to establish the effect of different designs of neonatal AED
trials on the sample size estimate from a power analysis. To this end, we modelled seizure time
courses based on real data, which allowed us to examine the influence of trial design on the
sample size for different outcome measures, AED protocol and delays in intervention at differ-
ent levels of AED efficacy.
Methods
This study was performed as a series of simulated AED trials for neonatal seizures which allows
direct comparison between different trial designs. The key prior knowledge required for realis-
tic simulations is the natural time course of seizure burden during neonatal seizures. Here, we
took advantage of two recently collected cohorts of long-term EEG recordings from neonates
with seizures due to hypoxic ischemic encephalopathy (HIE) [7, 10]. These cohorts contained
complete, second by second, quantification of seizure burden in two cohorts of neonates col-
lected before (n = 18, normothermic group) and after (n = 23) the introduction of hypothermia
as treatment for HIE [7, 10]. In these studies, data collectionwas conducted with approval
from the Clinical Research Ethics Committee of the Cork Teaching Hospitals, Ireland. Parental
written, informed consent was obtained for all newborns recruited for EEGmonitoring studies.
Trial Design for the Treatment of Neonatal Seizures
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All data were anonymised. For more details on the demographics and seizure burden of this
cohort see the S1 Appendix and Lynch et al. (2012 and 2014) [7, 10]. The most significant dif-
ference between these two cohorts was a lower overall seizure burden in neonates treated with
hypothermia.
Generation of a realistic model of neonatal seizure burden time courses
We first constructed a realistic model of seizure burden time courses that permitted the use of
large simulated cohorts. A lognormal functionwas found to adequately simulate the seizure
burden time course with the characteristic positive skewness that is seen in the distribution of
seizures over time. In other words, neonatal seizure burden has been shown to accumulate rap-
idly in the hours after seizure onset, followed by a more gradual accumulation towards seizure
offset [7]. It also results in smoothed time courses where seizures occur to some extent for the
entire period of simulation. The smoothing of any discontinuities in the seizure burden time
courses was required for the following reasons: 1) discontinuities generated by the response to
AED treatment and periods of missing data contaminate the normative seizure burden time
course resulting in the need for interpolation, 2) the systematic implementation of the RCT
simulations would result in invalid outcome measures in the presence of discontinuity, i.e. no
seizure burden (further, an AED would not be given if no seizures were present), 3) the func-
tion of seizure burden over time is not a raw value and must be calculated from the raw seizure
annotations, so smoothing the seizure burden can be considered as calculating the seizure bur-
den over a longer time period (see S1 Appendix). Notably, while smoothingmay reduce the
peak seizure burden, it does not significantly alter other important summarymeasures of sei-
zure burden such as the total seizure burden, the skew towards seizure onset, and the time
from seizure onset to the point of maximum seizure burden.
In order to generate a single seizure burden time course, the parameters of the lognormal
functionwere assumed to be random and were selected from a multi-variate distribution esti-
mated from real data. An example of the lognormal function fitted to real data and the lognor-
mal function fitted to all 41 neonates in the cohort are shown in Fig 1A and 1B. More details
on the process of simulating seizure burden time courses and the quality of fit of a lognormal
function to real data is outlined in S2 Appendix.
Simulation of therapeutic trials
The simulated seizure burden time courses were used in a power calculation for several ran-
domized control trials (RCT). Each RCT was defined using several variables: AED protocol,
average time relating to the administration of the intervention with respect to seizure onset
(Td), target level of trial AED efficacy and outcome measure.
Three different AED protocols were used (see Fig 1C): first line AED vs. placebo control,
first line AED vs. positive control (assumed to be phenobarbitone), and second line AED vs.
placebo control (with phenobarbitone as a first line). The efficacy of phenobarbitone was
assumed to be a 75% reduction in seizures for 3h [17]. The Td variable represents delays in the
clinical recognition of seizures and the speed of execution of the trial protocol and was varied
from 1h to 8h [18]. We used four AED efficacies from a maximum possible effect (100% reduc-
tion in seizures for 72h), to more typical effects (80% reduction for 12h, 80% reduction for 6h,
and 50% reduction for 12h) that parallel typical target levels of efficacy [4, 12, 13].
Five outcome measures were estimated from the simulated seizure burden time course (for
a graphical representation, see Fig 1C). 1) Total seizure burden: The total accumulated dura-
tion of seizures between seizure onset and seizure offset (or monitoring cessation). 2) Post-
intervention seizure burden for 1h: The accumulated duration of seizures in a 1h time period
Trial Design for the Treatment of Neonatal Seizures
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after the intervention. 3) Post-intervention seizure burden for 12h: The accumulated duration
of seizures in a 12h time period after the intervention. 4) Seizure burden response over 1h: The
accumulated duration of seizures in a one-hour time period before the intervention (baseline)
subtracted from the accumulated duration of seizures in a 1h time period after the intervention.
5) Seizure burden response over 12h: The accumulated duration of seizures in a one-hour base-
line period subtracted from the accumulated duration of seizures averaged across a 12h time
period after the intervention.
The total seizure burden is the most general measure of seizures in a neonate and maximis-
ing its reduction should have the most positive effect on long term neurodevelopmental out-
comes [15]. This outcome measure requires long term, continuous EEG recording from the
onset of seizures, which may be logistically challenging in many neonatal intensive care units
(NICUs). The post-intervention seizure burden takes into account the seizure burden after the
intervention in each patient while the seizure burden before the intervention is ignored. This
outcome measure requires a continuous EEG recording from the time of intervention, which is
achievable in most NICUs. The seizure burden response is commonly used in uncontrolled
studies and requires EEG recording during the pre- and post-intervention time periods.
Several published trials use the seizure burden response as the primary outcome measure [4,
5, 12, 13]. The advantage of the seizure burden response is that it is the only outcome measure
that can be used in an uncontrolled study. The total seizure burden has been used to assess
treatments such as hypothermia and the usefulness of EEGmonitoring to guide treatment [16,
19].
Estimating the sample size (power calculation)
The sample size was calculated using the mean and standard deviations of these outcome mea-
sures in simulated arms of the RCT. The sample size was defined as,
N ¼
4ðs2
1
þ s2
2
Þð1:96þ 0:842Þ
2
D
2
ð1Þ
where, σ1 and σ2 are the standard deviation of the outcome measure in the intervention and
control groups, respectively, and Δ is the effect size (Δ = μ2 − μ1 where μ1 and μ2 are the mean
of the outcome measure in the trial AED and control group, respectively) [20]. The constants
relate to the pre-selection of 80% power and a level of significance of 0.05 (two-sided test). An
equal number of patients in each group (N/2) was also assumed as per current practice in stud-
ies on treatments for neonatal seizures [4, 5, 13, 15, 16].
Fig 1. Seizure time courses and neonatal seizure treatment trial designs. The simulated seizure time courses used to estimate the
sample size for various designs of a randomized control trial. A) An example smoothed seizure time course from the cohort of Lynch et al.
(2015) plotted over the corresponding real seizure time course [10]. B) All 41 smoothed seizure time courses from the cohorts of Lynch et al.
(2012 and 2015) showing the variability of seizures in neonates (the black line in A and B refers to the same neonate) [7, 10]. SB/h is seizure
burden in minutes per hour; it is a measure of the short term intensity of seizures. Time is measured with respect to seizure onset. C) The
use of different AED protocols and outcome measures in RCT design. Each row defines a common outcome measure and each column
defines an AED protocol. Outcome measures are defined by the shaded areas: tSB row–total SB (blue shaded area), pSB row–post-
intervention SB (blue shaded area), and rSB row–SB response (blue shaded area subtracted from the red shaded area). Treatment delay is
the difference between seizure onset and the initiation of the trial protocol and is 2h in these examples. The level of AED efficacy in these
examples is an immediate 90% reduction in seizure burden. The trial drug is denoted as Dx. Existing or positive control anti-epileptic drug
(AED) effect was based on phenobarbitone: a 75% reduction in seizure burden for 3h. The asterisk denotes the cessation of the existing
AED effect (seizure reoccurrence).
doi:10.1371/journal.pone.0165693.g001
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Simulations and Analysis
A diagrammatic summary of the process of estimating sample size from simulated RCT is
shown in Fig 2. In order to calculate the sample size, the mean and standard deviation of each
outcome measure were estimated by simulating 50,000 neonates per group.
We first analysed the control group of several RCT designs in order to estimate how com-
monly used criteria of treatment success would be met. In these cases, we approximated the
control arm of a RCT by selecting the AED protocol, outcome measure and criterion for suc-
cessful seizure reduction that best matched the definitions from the literature: 1) first line AED,
success is an 80% seizure reduction from a 1h period before AED compared to a 1h period
after AED; 2) second line AED, success is an 80% seizure reduction from 2h before AED com-
pared to 2h period, 2h after AED; 3) second line AED, success is a 50% seizure reduction from
a 1h period before AED compared to a 24h period after AED [4, 12, 13]. We simulated the con-
trol group of the RCT for a range of Td (1h to 8h). The proportion of neonates that exceeded
the criterion for success was then calculated.
We then analysed the effect of each variable of RCT design independently by simulating
subgroups of RCTs where the variable of interest was altered while other variables were fixed.
We used a range of Td from 1h to 8h, three AED protocols, four AED efficacies and five out-
comemeasures resulting in 480 simulated trials.
The sample size with respect to each simulated RCT was considered as a random variable.
Changes in sample size due to changes in RCT variable were expressed as proportions or fold
changes. All values were summarised using the median, interquartile range and range where
applicable. The 95% confidence intervals (CI) of the sample and effect sizes were calculated
using bootstrap resampling (1000 iterations for each simulated RCT). In this case, the seizure
time course of each neonate in the dataset was considered as one sample. Differences in RCT
variables (Td, outcome measures, AED protocol) were tested using a Wilcoxon signed rank test
(a paired test). Finally, we compared the required sample sizes for a subgroup of neonates who
had received therapeutic hypothermia to a subgroup who had not received therapeutic hypo-
thermia (normothermic group). This is useful as therapeutic hypothermia has been shown to
reduce seizure burden in neonates with HIE and is now the standard of care in many NICUs
[19]. Comparisons between therapeutic hypothermia and normothermic groups were per-
formed usingMann Whitney U-tests (an unpaired test).
The trial simulation code was developedwith Matlab (Mathworks, Natick, MA, USA) and
will be made available on request.
Results
Evidence for the need of a control arm
We found that the placebo control arm of several RCTs had a perceptible rate of apparent suc-
cess in (Fig 3). This false positive rate was dependent on the definition of the outcome measure,
Td, and the criterion of successful seizure reduction.
Sample Size vs Td
Tables 1 and 2 show the required sample sizes across RCTs defined by a range of outcome mea-
sures, AED protocols and Td for two target levels of AED efficacy:80% seizure reduction for
12h and 100% seizure reduction for 72h. Tables 3 and 4 shows the corresponding effect sizes.
The median increase in sample size from Td = 1h to Td = 8h was 2.1 fold (IQR: 1.7–2.9) across
a range of outcome measures, AED protocols and AED efficacies (p<0.001; n = 60).
Trial Design for the Treatment of Neonatal Seizures
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Sample Size vs Outcome Measure
The choice of outcome measure resulted in the largest changes in the required sample size. In
general, long term outcome measures resulted in the largest sample sizes and short termmea-
sures resulted in the smallest sample sizes. The only exception was for RCTs with a positive
control where short term outcome measures had the highest sample size. The choice of out-
comemeasure resulted in a median difference in sample size of, at most, 30.7 fold (IQR: 13.7–
40.0) across a range of AED protocols, AED efficacies and delays (p<0.001; n = 96).
Fig 2. The RCT simulation used in this study. 1) Real seizure burden (SB) time courses were initially
modelled with a lognormal function. The probability density function (PDF) of the lognormal function
parameters across a cohort of 41 neonates was estimated. 2) RCT parameters including the AED protocol,
delay between seizure onset and intervention (Td), outcome measure (OM), and level of AED efficacy were
selected. A lognormal SB time course for each RCT arm was simulated by selecting lognormal parameters for
each arm of the RCT from a multi-variate random variable with the PDF defined previously. The effect of the
trial AED (and any other effects according to the AED protocol) was then applied to the SB time course in the
intervention arm. The OM was calculated from the SB time course for each RCT arm. This process was iterated
across 50000 simulated neonates and the mean and the standard deviation of the OM was then calculated and
used to estimate the effect and sample size.
doi:10.1371/journal.pone.0165693.g002
Fig 3. Nominal success rates due to a natural decay in seizure burden in neonates from a placebo
control group. Success in trial 1 (second line) 50% reduction in seizure burden measured in a 1h period
before placebo compared to the seizure burden in a 24h period after placebo. Success in trial 2 (second line)
is an 80% reduction in the seizure burden measured in a 2h period before placebo compared to the seizure
burden in a 2h period starting 2h after placebo. Success in trial 3 (first line) is an 80% reduction in the seizure
burden measured in a 1h period before placebo compared to the seizure burden in a 1h period after placebo.
The shaded areas denote the 95% confidence interval of the estimates.
doi:10.1371/journal.pone.0165693.g003
Trial Design for the Treatment of Neonatal Seizures
PLOS ONE | DOI:10.1371/journal.pone.0165693 November 8, 2016 8 / 14
Sample size vs AED protocol
In general, RCTs that included comparisons with a control group containing other AEDs (as
either positive controls or first line AEDs in a second line trial) required a higher sample size
than first line, placebo controlled trials; the median increase in sample size was 3.2 fold (IQR:
1.9–11.9) across a range of AED efficacies, delays and outcome measures (p<0.001; n = 320).
Table 1. The effect of trial design on sample size with an assumed trial drug efficacy of 80% reduction in seizure burden for 12h. Outcome mea-
sures (OM) are total seizure burden (tSB) in minutes, post-intervention seizure burden (pSB) in minutes measured over a duration specified by the subscript
in hours, seizure burden response (rSB) in minutes per hour, 1h pre-intervention vs. a post-intervention duration specified by the subscript in hours. Results
are presented as sample size (95% CI).
AED protocol OM Treatment delay (h)
1 2 4 6 8
1st line AED tSB 268 (136–440) 304 (162–508) 422 (236–724) 606 (348–1056) 870 (518–1508)
placebo control pSB1 26(18–34) 32(22–46) 46 (30–70) 58 (36–90) 68 (42–108)
pSB12 42(26–62) 50(30–76) 64 (38–100) 76 (46–120) 88 (52–140)
rSB1 28(18–44) 24(16–36) 32 (20–48) 40 (26–64) 50 (30–80)
rSB12 98(58–182) 102(62–182) 126 (72–234) 152 (86–288) 170 (100–326)
1st line AED tSB 532(284–902) 610(328–1058) 844 (474–1476) 1206 (708–2138) 1730(1040–3138)
positive control pSB1 608(402–870) 762(538–1190) 1076 (718–1820) 1372 (852–2340) 1654 (992–2860)
pSB12 64(40–100) 72 (44–116) 90 (54–142) 104 (62–166) 118 (70–192)
rSB1 5382 (3028–11158) 7836(4058–17230) 17552 (7004–31878) 23234 (9610–43934) 26444 (10970–67138)
rSB12 194(110–406) 224 (122–460) 316 (162–652) 390 (208–838) 434 (242–924)
2nd line AED tSB 446(252–770) 516 (294–886) 716 (428–1230) 1016 (616–1764) 1442 (874–2636)
placebo control pSB1 52(32–80) 58 (36–90) 68(42–108) 80 (48–126) 90 (54–144)
pSB12 70(42–110) 76 (46–120) 88(52–140) 98 (58–160) 108 (64–180)
rSB1 36(24–56) 40 (26–64) 50 (30–80) 56 (34–92) 64 (38–106)
rSB12 140(80–266) 152 (86–288) 170 (100–326) 184 (106–350) 196 (110–372)
doi:10.1371/journal.pone.0165693.t001
Table 2. The effect of trial design on sample size with an assumed trial drug efficacy of 100% reduction in seizure burden for 72h. Outcome mea-
sures (OM) are total seizure burden (tSB) in minutes, post-intervention seizure burden (pSB) in minutes measured over a duration specified by the subscript
in hours, seizure burden response (rSB) in minutes per hour, 1h pre-intervention vs. a post-intervention duration specified by the subscript in hours. Results
are presented as sample size (95% CI).
AED protocol OM Treatment Delay (h)
1 2 4 6 8
1st line tSB 40 (26–60) 46 (28–72) 62 (38–100) 86 (52–146) 118 (72–214)
Placebo pSB1 16 (10–22) 20 (14–28) 28 (18–44) 36 (22–56) 42 (26–68)
Control pSB12 26 (16–40) 32 (20–48) 40 (24–62) 46 (28–74) 54 (32–86)
rSB1 20 (14–30) 22 (14–30) 30 (20–46) 40 (24–62) 48 (30–76)
rSB12 62 (36–112) 70 (42–124) 94 (56–176) 118 (68–220) 134 (80–254)
1st line tSB 48 (30–76) 54 (34–86) 72 (44–116) 98 (60–172) 138 (82–260)
Positive pSB1 16 (10–22) 20 (14–28) 28 (18–44) 36 (22–56) 42 (26–68)
Control pSB12 34 (20–50) 38 (24–58) 44 (28–72) 52 (32–84) 58 (36–96)
rSB1 252 (176–380) 396 (256–584) 732 (444–1082) 990 (592–1544) 1198 (710–1906)
rSB12 102 (58–200) 128 (72–256) 192 (106–388) 244 (136–482) 278 (158–556)
2nd line tSB 64 (38–102) 72 (44–116) 96 (58–166) 132 (80–244) 182 (106–370)
Placebo pSB1 32 (20–50) 36 (22–56) 42 (26–68) 50 (30–78) 56 (34–90)
Control pSB12 44 (26–68) 46 (28–74) 54 (32–86) 60 (36–100) 68 (40–112)
rSB1 34 (22–54) 40 (24–62) 48 (30–76) 54 (34–90) 62 (38–102)
rSB12 108 (62–200) 118 (68–220) 134 (80–254) 148 (86–278) 158 (90–300)
doi:10.1371/journal.pone.0165693.t002
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Effects on sample size due to therapeutic hypothermia
Required sample sizes were on median 2.6 times greater (IQR: 2.4–3.0) for a RCT based on sei-
zure burden time courses from a subgroup of neonates treated with hypothermia compared to
normothermic neonates (p<0.001; n = 480). More detailed results from the analysis of a sub-
group of neonates treated with therapeutic hypothermia is shown in S3 Appendix.
Discussion
Our results suggest that the design of a RCT for assessing the efficacy of an AED in neonates
with seizures is challenging with orders of magnitude differences in the required sample size
possible depending on the choices of AED protocol, outcome measure, and Td. The high vari-
ability in the magnitude of seizure burden over time within and across neonates translates to
Table 3. The effect of trial design on effect size with an assumed trial drug efficacy of 80% reduction in seizure burden for 12h. Outcome measures
(OM) are total seizure burden (tSB) in minutes, post-intervention seizure burden (pSB) in minutes measured over a duration specified by the subscript in
hours, seizure burden response (rSB) in minutes per hour, 1h pre-intervention vs. a post-intervention duration specified by the subscript in hours. The maxi-
mum possible effect for each trial is given in the Table 4. The effect size of tSB and pSB12 are equal as the assumed efficacy of the trial AED effect is 12h.
The effect size of pSB1 and rSB1 are also equal as the rSB is measured in minutes per hour and not as a proportion. Results are presented as effect size
(95% CI).
AED protocol OM Treatment delay (h)
1 2 4 6 8
1st line AED tSB & pSB12 98.1 (54.2–94.9) 91.3 (48.7–91.4) 77.4 (39.5–81.0) 65.1 (31.5–70.4) 54.9 (25.4–60.5)
placebo control pSB1 & rSB1 11.4 (9.2–13.4) 11.3 (8.5–13.6) 10.0 (7.0–12.7) 8.4 (5.6–11.2) 7.0 (4.5–9.7)
rSB12 8.2 (4.5–7.9) 7.6 (4.1–7.6) 6.3 (3.3–6.7) 5.3 (2.6–5.9) 4.5 (2.1–5.0)
1st line AED tSB & pSB12 66.9 (29.9–58.4) 61.3 (27.0–54.9) 51.5 (21.5–47.6) 43.5(17.3–40.9) 36.8 (14.0–35.0)
positive control pSB1 & rSB1 0.7 (0.6–0.8) 0.7 (0.5–0.8) 0.6 (0.4–0.8) 0.5 (0.4–0.7) 0.4 (0.3–0.6)
rSB12 5.6 (2.5–4.9) 5.1 (2.2–4.6) 4.2 (1.8–4.0) 3.5 (1.4–3.4) 3.0 (1.2–2.9)
2nd line AED tSB & pSB12 70.9 (35.2–75.3) 64.9 (31.5–70.4) 54.8 (25.4–60.5) 46.5 (20.6–51.8) 39.8 (16.9–44.6)
placebo control pSB1 & rSB1 9.2 (6.3–12.0) 8.4 (5.6–11.2) 7.0 (4.5–9.7) 5.9 (3.6–8.4) 4.9 (2.9–7.2)
rSB12 5.8 (2.9–6.3) 5.3 (2.6–5.9) 4.5 (2.1–5.0) 3.8 (1.7–4.3) 3.3 (1.4–3.7)
doi:10.1371/journal.pone.0165693.t003
Table 4. The effect of trial design on effect size with an assumed trial drug efficacy of 100% reduction in seizure burden for 72h (the maximum
possible effect). Outcome measures (OM) are total seizure burden (tSB) in minutes, post-intervention seizure burden (pSB) in minutes measured over a
duration specified by the subscript in hours, seizure burden response (rSB) in minutes per hour, 1h pre-intervention vs. a post-intervention duration specified
by the subscript in hours. The effect size of pSB1 and rSB1 are equal as the rSB is measured in minutes per hour and not as a proportion. Results are pre-
sented as effect size (95% CI).
AED protocol OM Treatment Delay (h)
1 2 4 6 8
1st line tSB 212.3 (54.2–94.9) 198.1 (48.7–91.4) 170.8 (39.5–81.0) 147.0 (31.5–70.4) 127.0 (25.4–60.5)
Placebo pSB1 & rSB1 14.2 (9.2–13.4) 14.1 (8.5–13.6) 12.5 (7.0–12.7) 10.5 (5.6–11.2) 8.8 (4.5–9.7)
Control pSB12 122.7 (54.2–94.9) 114.1 (48.7–91.4) 96.6 (39.5–81.0) 81.1 (31.5–70.4) 68.3 (25.4–60.5)
rSB12 10.2 (4.5–7.9) 9.5 (4.1–7.6) 8.0 (3.3–6.7) 6.7 (2.6–5.9) 5.7 (2.1–5.0)
1st line tSB 181.0 (29.9–58.4) 168.1 (27.0–54.9) 145.0 (21.5–47.6) 125.3 (17.3–40.9) 108.9 (14.0–35.0)
Positive pSB1 & rSB1 3.6 (0.6–0.8) 3.5 (0.5–0.8) 3.1 (0.4–0.8) 2.6 (0.4–0.7) 2.2 (0.3–0.6)
Control pSB12 91.4 (29.9–58.4) 84.2 (27.0–54.9) 70.7 (21.5–47.6) 59.4 (17.3–40.9) 50.2 (14.0–35.0)
rSB12 7.6 (2.5–4.9) 7.0 (2.2–4.6) 5.8 (1.8–4.0) 4.9 (1.4–3.4) 4.1 (1.2–2.9)
2nd line tSB 158.3 (35.2–75.3) 146.8 (31.5–70.4) 126.8 (25.4–60.5) 110.1 (20.6–51.8) 96.2 (16.9–44.6)
Placebo pSB1 & rSB1 11.5 (6.3–12.0) 10.5 (5.6–11.2) 8.8 (4.5–9.7) 7.3 (3.6–8.4) 6.1 (2.9–7.2)
Control pSB12 88.5 (35.2–75.3) 81.1 (31.5–70.4) 68.3 (25.4–60.5) 57.8 (20.6–51.8) 49.3 (16.9–44.6)
rSB12 7.3 (2.9–6.3) 6.7 (2.6–5.9) 5.7 (2.1–5.0) 4.8 (1.7–4.3) 4.1 (1.4–3.7)
doi:10.1371/journal.pone.0165693.t004
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high variability in outcome measures of trial AED efficacy. The present findings offer three
practical suggestions for how to optimize a study in terms of minimizing the required sample
size and maximizing the validity.
Trials must incorporate a control group. A control group is necessary as simulations show a
non-negligible percentage (5–85%) of patients treated with a placebo can fulfil criteria of treat-
ment success due to the natural reduction in seizures over time. This is commonly seen in drug
trials for epilepsy [2]. Indeed, it is plausible to speculate that this natural seizure reductionmay
contribute, in varying degrees, to the reported treatment effects observed in prior uncontrolled
studies [13, 21, 22].
Trials should aim to minimise, and control for differences in, Td between intervention and
control groups. A reduction in Td reduces the required sample size and increases the measured
effect. A change in Td of several hours can double the required sample size. This implies that
the entire study protocol needs to proceed very rapidly, advancing from patient identification
to recruitment and AED administration within a few hours of seizure onset. This is technically
achievable in high level NICUs as modern clinical practice can operate within short time
frames as long as early EEGmonitoring of all high-risk infants is standard procedure [23, 24].
The dependency of the effect size on Td indicates that any differences in Td between interven-
tion and control groups must be controlled for in statistical analyses.
The combination of AED protocol and the choice of outcome measure should be carefully con-
sidered as a mismatch may result in an order of magnitude increase in the required sample size.
Among outcome measures and AED protocols, post-intervention seizure burden in a first line
AED vs. placebo controlled RCT required the lowest required sample size. RCTs using short-
term seizure burden response in a positive control trial had the highest required sample size.
For other AED protocols, RCTs with the total seizure burden as an outcome measure required
large sample sizes. The post-intervention seizure burden was, in general, the outcome measure
that resulted in RCTs with the lowest required sample size depending on the post-intervention
analysis period. The ability to alter the post-intervention period is advantageous as investiga-
tors can nominate a desired trial AED effect time which caters for the incorporation of rescue
medications in trial design for seizures that do not respond to treatment or reoccurwith signifi-
cant intensity; medications that if given during the analysis period confound subsequent statis-
tical analyses. Another advantage of the post-intervention seizure burden is that it does not
require the monitoring of a baseline period (seizure burden response) or the recording of sei-
zure onset (total seizure burden).
Our present findings are supported by the literature both in terms of studies that did, and
did not find, significant differences in seizure burden. In the highly cited and important study
of Painter et al. (1999), no significant differences in seizure burden response between pheno-
barbitone and phenytoin were found in a cohort of 59 neonates [4]. Our findings suggest that
this trial was powered to detect differences in seizure efficacy considerably larger than 25%
betweenAEDs (see positive control, first line, rSB1 in Table 2 – 75% efficacy for positive control
vs 100% efficacy for trial drug); in other words, the efficacyof phenobarbitone was not greater
than 25% different from phenytoin. A recent uncontrolled study observedAED efficacywith a
measure similar to the seizure burden response in a cohort of 19 neonates [17]. In an RCT with
a similar design and effect size (placebo control, first line, rSB1, Td = 1h in Table 1); our model
would have predicted a sample size of 14 neonates per group. Low et al. (2012) also showed a
significant reduction in total seizure burden in neonates treated with hypothermia in a cohort
of 31 neonates [19]. In this case, our model would predict a cohort of 40 neonates based on a
similar effect size; equivalent to an AED effect of 100% for 72h given within 1h of seizure onset
(see placebo control, first line, TSB in Table 2). The use of simulation adds further context to
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these studies which can be useful for clinicians who are considering altering their treatment
protocols in response to RCT findings.
RCTs may be able to reduce the required sample size by assumingmore conservative levels of
AED efficacy and considering post-hoc stratification of patients according to the intensity of sei-
zure burden. This approach was used successfully, in a recent study that initially found no signifi-
cant reduction in total seizure burden due to AED treatment managed with EEGmonitoring in a
cohort of 35 neonates despite a large effect size; however, a significant reduction in total seizure
burden was found in a subgroup of neonates with seizures but without status epilepticus [16].
A potential limitation in our work is that only one aetiology (HIE) of neonatal seizures was
used as the basis of our simulations. While systematic comparative characterization of seizure
time courses is not available across different aetiologies, the present data and clinical experi-
ence suggest that seizure time courses may vary with aetiology [9]. This implies that our sample
size estimates apply to treatment trials only on neonates with HIE. If sample size estimates for
a general cohort of neonates with seizure are required then the use of neonates with HIE pro-
vides the best initial data as 1) HIE is the most common aetiology of seizure and 2) the tempo-
ral evolution of seizures over time is well defined in this aetiology [6, 7, 10, 25]. The seizures
used as a basis for simulations are detected using the visual interpretation of the multi-channel
EEG [23]. While this method is the gold standard for seizure detection, it is not perfect and its
reliability is reduced when seizures are infrequent or of short duration [26]. We do not expect
this to have had a major effect on the results as any variability due to reliability will be vastly
outweighed by the variability in seizure time courses across neonates. A technical limitation of
our work is the use of simulated seizure burden time courses based on a real but limited dataset
of neonates where seizures were treated with AEDs. This reduces the precision of the sample
size estimates, however, the relationships between outcome measure, trial protocol, treatment
delay, level of trial AED efficacy and sample size are statistically significant.
Our present work shows that it is, in principle, possible to measure the short term efficacy
of AEDs in a relatively small cohort of neonates. A more difficult challenge is determining if
one AED is more effective than another (RCTs with a positive control); a proposition that
more closely achieves clinical equipoise [27]. In order to minimise the sample size, these RCTs
require long term outcome measures of seizure burden and must assume a high level of trial
AED efficacy far in excess of the current generation of AEDs (see Table 2). This assumption is
more critical as modern day NICUs are highly effective positive controls that take advantage of
EEGmonitoring to target AED therapy and use therapeutic hypothermia for HIE which have,
independently, been shown to significantly reduce seizure burden [16, 19].
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